Abstract
5582 Background: SNS-595 is under clinical investigation in acute leukemia and ovarian cancer. Clinical responses have been observed in these indications, and in non-small cell and small cell lung cancers. SNS-595 is a replication-dependent DNA damaging agent that causes irreversible G2 arrest and apoptosis via DNA intercalation and topoisomerase II inhibition. A phase 2 study of single agent SNS-595 in ovarian cancer was initiated based on phase 1 clinical activity in patients (pts) with ovarian cancer, including one partial response (PR). Methods: Pts had advanced platinum resistant (progressed during or relapsed within 6 months of platinum based therapy) epithelial ovarian cancer who had progressive disease after 1 or 2 prior platinum containing regimens; pts could have received an additional biologic or non-platinum therapy after becoming platinum-resistant. A GOG PS of 0–1 and adequate hematologic, hepatic and renal status were required. Pts received 48 mg/m2 SNS-595 by 10 minute IV infusion on Day 1...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
